본문 바로가기

Phase II trial of rituximab plus CVP combination chemotherapy for advanced stage marginal zone lymphoma as a first-line therapy: Consortium for Improving Survival of Lymphoma (CISL) study

문서 유형
연구출판물 · 학술지 논문
등재
SCIEScopus
저널 순위
JCR Q2Scopus Q2
저널
ANNALS OF HEMATOLOGY91(4) · pp.543 · 2012
피인용
Web of Science 48
JCR IF
JCR 2011 2.615
ISSN
0939-5555

저자

  1. Kang, Hye Jin국립암센터, Korea Inst Radiol & Med Sci, Dept Internal Med, KO
  2. Kim, Won Seog성균관대학교, Sch Med, Samsung Med Ctr, KO
  3. Kim, Seok Jin성균관대학교, Sch Med, Samsung Med Ctr, KO
  4. Lee, Je-Jung전남대학교, Hwasun Hosp, Dept Hematol Oncol, KO
  5. Yang, Deok-Hwan전남대학교, Hwasun Hosp, Dept Hematol Oncol, KO
  6. Kim, Jin Seok연세대학교, Coll Med, Dept Internal Med, KO
  7. Lee, Se-Ryeon고려대학교, Dept Internal Med, Sch Med, KO
  8. Lee, Gyeong-Won경상대학교, Sch Med, Dept Internal Med, KO
  9. Kim, Hyo Jung한림대학교, Sacred Heart Hosp, Hallym Med Ctr, KO
  10. Kim, Ho Young한림대학교, Sacred Heart Hosp, Hallym Med Ctr, KO
  11. Oh, Sung Yong동아대학교, Coll Med, Dept Internal Med, KO
  12. Kim, Hugh Chul아주대학교, Dept Internal Med, KO
  13. Eom, Hyeon-Seok국립암센터, Res Inst & Hosp, Hematol Oncol Clin, KO
  14. 정주섭부산대학교, 의과대학, 의과학과, KO
  15. Park, Jinny가천대학교, Dept Internal Med, KO
  16. Suh, Cheolwon울산대학교, Coll Med, Dept Oncol, KO
  17. Ryoo, Baek-Yeol국립암센터, Korea Inst Radiol & Med Sci, Dept Internal Med, KO

초록

We conducted a multicenter, phase II trial to investigate the efficacy and safety of rituximab plus CVP (R-CVP) combination therapy for patients with previously untreated stage III or IV marginal zone lymphoma (MZL). The treatment consisted of rituximab 375 mg/m(2), cyclophosphamide 750 mg/m(2) and vincristine 1.4 mg/m(2) (maximum 2.0 mg) being given intravenously on day 1 and oral prednisolone 100 mg on days 1-5. The treatment was repeated every 3 weeks and this was continued for six or eight cycles. Forty-two patients were enrolled from 13 institutes in Korea. Among them, two patients were dropped after the first and second cycles of chemotherapy, respectively, without evaluation. The 40 patients received a total of 287 cycles of R-CVP chemotherapy. The overall response rate was 88% (95% CI, 77-98%) with 24 complete responses (60%). The median duration of response was 28.3 months. After a median follow-up of 38.2 months, the estimated 3-year progression-free survival and overall survival were 59% and 95%, respectively. There were 30/287 cycles (11%) and 5/287 cycles (2%) of grade 3 or 4 neutropenia and febrile neutropenia, respectively. The R-CVP regimen can be an effective and tolerable first-line immunochemotherapy regimen for advanced stage MZL.

키워드

CVPFirst-lineImmunochemotherapyMarginal zone lymphomaRituximabB-CELL LYMPHOMAANTI-CD20 MONOCLONAL-ANTIBODYNON-HODGKINS-LYMPHOMAADVANCED FOLLICULAR LYMPHOMATISSUE LYMPHOMAMALT TYPECHOP CHEMOTHERAPYFLUDARABINE PHOSPHATECLINICAL PRESENTATIONORAL FLUDARABINE

식별자

WoS UID
000301243600009